Telehealth company
Lavender Sky Health
Official website and treatment plan pricing page reviewed
Unclaimed profileReviewed Aug 2, 2026
Telehealth service profile
- Care model
- Telehealth weight management and wellness practice offering custom-compounded and brand-name GLP-1 treatment plans
- Medication access
- Compounded semaglutide and tirzepatide (some with B12, glycine, or niacinamide additives), brand-name Zepbound, Mounjaro, Wegovy, and Ozempic, plus B vitamin boosters, amino acid boosters, glutathione, NAD+, sermorelin, lipotropics, and aesthetic wellness treatments.
- Provider model
- Consultations by phone, video, or e-consult with a provider; unlimited support from the healthcare provider and patient support team for the treatment duration.
- Pharmacy pathway
- Prescriptions go to a vetted network of accredited compounding pharmacies (ReviveRx, Nova/AbsoluteRx, Hallandale, Strive, Empower, Southend) that typically process and ship in 2-7 business days; brand-name prescriptions go to a local pharmacy, Lilly Direct, or NovoCare.
- Insurance support
- Cash-pay treatment plans; for brand-name medications patients check pricing and availability with their chosen pharmacy, and Wegovy pens are noted at a $499 per month direct-to-patient price.
- Availability
- Each partner pharmacy is licensed to ship to a specific list of states, so medication availability depends on patient location; availability of any particular compounded medication cannot be guaranteed at any time.
Editorial record
Publishes per-pharmacy compounded GLP-1 pricing across six partner pharmacies (ReviveRx, Nova/AbsoluteRx, Hallandale, Strive, Empower, and Southend), such as Hallandale tirzepatide at $219 for a 10-week supply (about $110 per month) and Empower semaglutide/B12 at $235 for an 8-week supply (about $118 per month). A standard brand-name plan costs $25 per month plus the cost of medication, with prescriptions sent to a local pharmacy, Lilly Direct, or NovoCare.
Profile ownership: unclaimed. Company representatives will be able to propose identity and catalog updates without changing editorial or regulatory records.